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Background: The role played by T helper cytokines under chronic, low grade inflammation as seen in type-2
Diabetes Mellitus (T2DM) and Coronary Artery Disease (CAD) co-morbidity is less well studied. In the present study,
we measured the serum levels of both Th1 and Th2 cytokines and correlated it with clinical risk factors for T2DM
(Insulin Resistance (IR), Glycated haemoglobin (HbA1c)) and CAD (C-Reactive Protein (CRP), Intima Media Thickness
(IMT) and Augmentation index (AGI)) in T2DM subjects with/without CAD.
Methodology: The study subjects were recruited from Chennai Urban Rural Epidemiology Study (CURES). Serum
cytokine profile was determined by multiplex cytokine assay in Control (n = 61), T2DM (n = 60), CAD (n = 23) and
T2DM-CAD (n = 21) subjects.
Results: T2DM subjects showed a mixed Th1-Th2 profile. CAD subjects presented a Th1 profile with modest Th2
suppression while T2DM-CAD subjects showed enhanced Th1 profile with strong suppression of Th2 cytokines. Both
Th1 and Th2 cytokines showed a positive correlation with FPG, HbA1c, hsCRP, IMT and AGI. Logistic regression analysis
revealed a significant association of IL-12 (OR = 9.3; 95% CI = 3.2-70.7; p = 0.016), IFN-γ (OR = 2.8; 95% CI = 2.7-2.9,
p = 0.010), IL-4 (OR = 2.7; 95% CI 2.7-2.7, p = 0.010), IL-5 (OR = 1.1; 95% CI = 1.0-1.4; p = 0.003) and IL-13 (OR = 2; 95%
CI = 1.7-2.6; p = 0.017) with T2DM-CAD.
Conclusion: In conclusion, from the present study it appears that transition from T2DM or CAD to T2DM-CAD
co-morbidity is associated with strong down regulation of Th2 cytokines and enhancement of Th1 responses.
Keywords: CAD, T2DM, IL-2, IL-12, IFN-γ, IL-4, IL-5, IL-13Introduction
Chronic, low grade inflammation with nitrosative stress
has now been identified as an essential component of both
Type-2 Diabetes Mellitus (T2DM) and Coronary Artery
Disease (CAD) [1-3]. The excessive morbidity and mor-
tality seen in T2DM subjects is primarily due to the in-
creased incidence of cardiovascular diseases (including
CAD) in these subjects accounting for 22% of total
deaths in 2008 and is projected to increase to 26% by
2030 (World Health Statistics, 2008). Apart from the
traditional risk factors of T2DM and CAD such as obesity,
hypertension and dyslipidemia, chronic inflammation has* Correspondence: cvaravindhan@gmail.com
1AU-KBC Research Centre, MIT Campus of Anna University, Chennai 600 044,
India
Full list of author information is available at the end of the article
© 2014 Madhumitha et al.; licensee BioMed C
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.now emerged as a major risk factor for both these condi-
tions [1]. The presence of activated T-cells in human ath-
erosclerotic plaque (in the case of CAD) and in adipose
tissue (in the case of T2DM) has been identified several
years ago indicating the involvement of adaptive immunity
in these disease conditions [4]. Upon activation, T lym-
phocytes differentiate into T-helper (Th)1 and Th2 subsets
secreting either Th1 (Interferon (IFN)-γ and Interleukin
(IL)-2) or Th2 cytokines (IL-4, IL-5 and IL-13) respectively
[5]. IL-12 has long been identified as the master controller
of Th1 differentiation while recently, IL-33 has emerged
as a master regulator of Th2 differentiation [5,6]. The role
played by the pro-inflammatory cytokines such as TNF-α,
IL-6 and IL-1β in atherogenesis and insulin resistance has
been well documented [7-9]. A recent study has indicated
IL-6 and activin-A as major risk factors for cardiovascularentral Ltd. This is an Open Access article distributed under the terms of the
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known is the role played by T-cell cytokines under condi-
tions of T2DM and CAD. Even less studied is the role
played by these cytokines under conditions of T2DM-
CAD co-morbidities. In these subjects, inflammation asso-
ciated with one condition can augment/synergize with the
inflammation associated with the other condition. Previ-
ously, we have reported mixed Th1-Th2 serum cytokine
profile in subjects with metabolic syndrome (MS), a major
risk factor for T2DM (if not present already) and CAD [7].
In the present study, we measured the serum levels of
both Th1 and Th2 cytokines and correlated it with clinical
risk factors for T2DM (Insulin Resistance (IR), Glycated
haemoglobin (HbA1c)) and CAD (C-Reactive Protein
(CRP), Intima Media Thickness (IMT) and Augmentation
index (AGI)) in subjects with T2DM with/without CAD.
Methodology
The study subjects were recruited from the Chennai
Urban Rural Epidemiological Study (CURES), an on-
going epidemiological study conducted on a representative
population (≥20 years old) of Chennai (formerly Madras),
the fourth largest city in India. The methodology of the
study has been published elsewhere [11]. In brief, 26,001 in-
dividuals were recruited for the Phase 1 of the urban com-
ponent of CURES, using a systematic random-sampling
technique. Fasting capillary blood glucose was determined
using an OneTouch_ Basic_ glucometer (Lifescan, a
Johnson & Johnson Company, Milpitas, CA) in all
subjects. In Phase 2 of CURES, all the known diabetes
subjects in Phase 1 were invited to the centre for
detailed studies on vascular complications. In Phase 3
every 10th subject in Phase 1 was invited for clinical,
biochemical, microvascular, and macrovascular exami-
nations. For the present study, the following subjects
were randomly selected from Phase 3 of CURES and
were allocated into the following groups:
Group 1 (n = 61): Subjects who had normal glucose
tolerance (Control)
Group 2 (n = 60): Subjects with known T2DM
Group 3 (n = 23): Subjects with known CAD
Group 4 (n = 21): Subjects with both T2DM and CAD
Inclusion and exclusion criteria
The inclusion criteria were patients within the normal
range of white blood cells to minimize the confounding
effect of infections. The exclusion criteria were patients
with type-1 diabetes and patients with a previous diagnosis
of urolithiasis, liver cirrhosis, congestive heart failure,
chronic lung diseases, chronic infections or viral hepatitis.
Institutional ethical committee approval from the Madras
Diabetes Research Foundation Ethics Committee was
obtained (Ref No-MDRF-EC/SOC/2009//05) and writteninformed consent was obtained from all the study par-
ticipants. Subjects with self reported diabetes receiving
treatment were classified as “known diabetes subjects.”
CAD was diagnosed based on positive medical history
(documented myocardial infarction (MI), angina pec-
toris and coronary artery bypass graft) and/or ischemic
changes on a conventional 12-lead ECG which included
ST-segment depression (Minnesota codes 1-1-1 to 1-1-7)
or Q-wave changes (Minnesota codes 4–1 to 4–2) [12].
Absence of CAD was based on absence of history of
angina or MI and normal ECG.
Anthropometric measurements and biochemical
parameters
Anthropometric measurements including height, weight,
and waist circumference, were obtained using standardized
techniques. The body mass index (BMI) was calculated
as the weight in kilograms divided by the square of
height in meters. Fasting plasma glucose (FPG) (glucose
oxidase-peroxidase method), serum cholesterol (choles-
terol oxidase-peroxidase- amidopyrine method), serum triglyc-
erides (glycerol phosphate oxidase-peroxidase-amidopyrine
method), high density lipoprotein cholesterol (HDL-C)
(direct method-polyethylene glycol-pretreated enzymes),
and creatinine (Jaffe’s method) were measured using a
Hitachi-912 Autoanalyser (Hitachi, Mannheim, Germany).
The intra- and inter assay coefficient of variation for
the biochemical assays ranged between 3.1% and 5.6%.
Glycated hemoglobin (HbA1c) was estimated by high
pressure liquid chromatography using a variant machine
(Bio-Rad, Hercules, CA). The intra- and inter-assay co-
efficient of variation of HbA1c was less than 5%. The
plasma concentrations of high-sensitivity C-reactive pro-
tein (hsCRP) were measured by high sensitive nephelo-
metric assay. The intra- and the inter-assay coefficients of
variation for hsCRP were 4.2% and 6.8%, respectively, and
the detection limit was 0.15 mg/L. Both the intra and inter
assay variations were determined in our biochemical lab.
Measurement of intima media thickness and arterial
stiffness
The method used for measurement of carotid intima
media thickness (IMT) has been previously described [13].
The intima plus medial thickness of the right common
carotid artery was determined using a high-resolution B-
mode ultrasonographic system (Logic 400 GE, Milwaukee,
Wisconsin) with an electrical linear transducer mid fre-
quency of 7.5 MHz. The axial resolution of the system
was 0.3 mm. The images were recorded, as well as
photographed. Scanning was performed for an average
of 20 minutes. IMT as defined by Pignoli and Longo
[13] was measured as the distance from the leading edge
of the first echogenic line to the second echogenic line.
The mean of the 6 IMT measurements (3 from the far
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tative value for each subject. The scanning was done
using fine manipulations of the transducer, to visualize,
with maximum clarity, the double-line pattern of the
IMT both at the near and far wall of the artery.
Arterial stiffness was measured using the Sphygmocor
apparatus (Sphygmocor BPAS-1; PWV Medical, Sydney,
Australia). In brief, a high-fidelity micromanometer
(SPC-301; Millar Instruments, Houston, Texas) was used
to flatten but not occlude the right radial artery, using
gentle pressure. When the 2 surfaces are flattened, cir-
cumferential pressures are equalized and an accurate
pressure waveform can be recorded. Data were collected
directly into a portable microcomputer. The system soft-
ware allowed on-line recording of the peripheral wave-
form, which was assessed visually to ensure that the best
possible recording was obtained and that artifacts from
movement were minimized. After 20 sequential wave-
forms had been acquired, the integral software was used
to generate an averaged peripheral and corresponding
central waveform that was used for the determination of
the Agumentation Index (AGI). AGI was defined as the
difference between the first and second peaks of the
central arterial waveform, expressed as a percentage of
the pulse pressure [14].
Estimation of levels of serum cytokines
The levels of cytokines (IL-2, IL-12, IFN-γ, IL-4, IL-5,
and IL-13) in the serum were measured using a Bio-Plex
multiplex cytokine bead assay system (Bio-Rad). The
lower detection limits were 16 pg/mL for IL-2, 0.3 pg/mL
for IL-4, 2.08 pg/mL for IL-5, 2.78 pg/mL for IL-12,
2.22 pg/mL for IL-13, 2.14 pg/mL for IFN- γ. The intra-
and interassay coefficients of variation for multiplex assay
were less than 5%.Statistical analysis
Data are expressed as geometric mean values. Student
t-test was used to compare groups for continuous vari-
ables, whereas χ2 test or Fisher exact test (as appropriate)
was used to compare proportions. The Mann–Whitney
U test was used in case of non-normally distributed
parameters to compare means. Spearman correlation
analysis was carried out to determine the association of
serum cytokine levels with clinical parameters. Multivari-
ate Logistic regression analysis was used to determine the
association of serum cytokines with T2DM-CAD. Kruskal-
Wallis test was used for multiple parameters that did not
show normal distribution. Multiple comparisons were cor-
rected using the Holm’s correction for each set of analysis.
All the analyses were done using SPSS statistical package
(Version 20.0; SPSS, Chicago, IL) and P value less than
0.05 was considered significant.Results
Table 1 shows the clinical and biochemical characteristics
of the study subjects. T2DM subjects were significantly
older and had higher BMI compared to controls (p < 0.05).
As expected they had significantly higher fasting plasma
glucose and HbA1C (p < 0.0001). Dyslipidemia and hyper-
tension was observed in 42% and 32% of the subjects re-
spectively. Their renal parameters such as urea, creatinine
and microalbuminuria were within the normal limits (Urea-
10–20 mg/dL; Creatinine- 0.7-1.3 mg/dL; Microalbumi-
nuria: <30 mg). The CAD subjects were relatively younger
and had normal BMI compared to T2DM subjects. This
observation is in line with the previous studies which have
reported premature CAD in south Indian population and
the higher susceptibility of this ethnic group for CAD [15].
These subjects were non-diabetic and hence had normal
fasting plasma glucose and HbA1c levels. Dyslipidemia
and hypertension was observed in 26% and 13% respect-
ively. Urea, creatinine and microalbuminuria levels were
within the normal range. The subjects with T2DM-CAD
co-morbidities were significantly older compared to the
control and CAD subjects. 24% of them were obese,
67% had hypertension and 38% showed dyslipidemia.
They had significantly higher fasting plasma glucose
and HbA1c values. However the renal parameters were
within the normal limits.
To determine serum Th1 cytokine profile the levels of
IL-2, IL-12 and IFN-γ were estimated in the study
groups (Figure 1). As can be seen in Figure 1, significantly
high levels of IFN-γ (but not IL-12) were seen in the
T2DM group while significantly elevated levels of both
IL-12 and IFN-γ were seen in CAD and T2DM-CAD
groups compared to controls. Overall the levels of IFN-γ
were not significantly different between T2DM, CAD and
T2DM-CAD groups. IL-2 levels were not significantly
different between the groups (Fig 1a). Next, the levels of
Th2 cytokines IL-4, IL-5 and IL-13 were determined in
the study groups (Figure 2). As can be seen in Figure 2,
significantly elevated levels of both IL-4 and IL-13 were
seen in the T2DM group while significantly low levels of
IL-5 were seen in the CAD group, compared to controls.
T2DM-CAD subjects had significantly lower levels of all
the three Th2 cytokines compared to that of T2DM group,
indicating strong Th2 suppression.
Additional file 1: Table S1 shows Spearman’s correlation
between the mean cytokine levels and the T2DM and
CAD risk factors. IL-2 showed a negative correlation with
Diastolic BP (r = −0.158; P = 0.046) and positive correl-
ation with AGI (r = 0.577, P < 0.0001). IL-12 showed a
negative correlation with HbA1C (r = −0.212, P = 0.011)
and VLDL (r = −0.183, P = 0.026). IFN-γ showed a positive
correlation with FPG (r = 0.228; P = 0.004) and HbA1C
(r = 0.339; p < 0.0001) whereas negative correlation with
IMT (r = −0.328, p = 0.011). IL-4 showed a positive
Figure 1 Serum levels of Th1 cytokines (IL-2, 12 and IFN-γ) in the study groups. Serum levels of IL-2 (a), IL-12 (b) and IFN-γ (c) were
determined in control (NGT), T2DM, CAD and T2DM-CAD subjects by multiplex cytokines assay. Each dot represents individual values with the
horizontal line representing the geo mean. Statistical significance was determined by non-parametric Kruskal–Wallis one-way analysis of variance
and p < 0.05 was considered significant.
Table 1 Clinical and biochemical characteristics of the study subjects
Clinical parameters Control (NGT) T2DM CAD T2DM_CAD
n = 61 n = 60 n = 23 n = 21
Age (Years) 39.6 ± 13.7 56.4 ± 13.9a*** 38.7 ± 15.8 60.9 ± 10.7c***
Body mass index (kg/m2) 23.19 ± 4.8 25.5 ± 5.2 21.1 ± 4.3 23.2 ± 4
Systolic BP (mm Hg) 114 ± 9.5 125 ± 2.2a** 122.5 ± 20.6 142.4 ± 19.9b**c**
Diastolic BP (mm Hg) 74.98 ± 8.5 77.2 ± 9.0 71.8 ± 10.03 87.3 ± 11.04b*
Fasting plasma glucose (mg/dL) 84.9 ± 9.1 158.9 ± 67.5a*** 85.8 ± 12.5 136.2 ± 41.4c***
Glycated haemoglobin (%) 5.3 ± 0.37 8.5 ± 1.9a*** 5.4 ± 0.5 7.6 ± 0.8c**
Total serum cholesterol (mg/dL) 174.5 ± 34.08 173.3 ± 46.02 188.2 ± 81.2 182.3 ± 37.1
Serum triglycerides (mg/dL) 108.2 ± 51.1 168.4 ± 100.4a*** 105.1 ± 54.6 140.1 ± 77.4
HDL-cholesterol (mg/dL) 43 ± 7.9 40 ± 9.1 47.7 ± 12.6 41.9 ± 11.9
LDL-cholesterol (mg/dL) 107.7 ± 28.7 98.5 ± 37.9 119.5 ± 73.4 112.4 ± 33.3
VLDL-cholesterol (mg/dL) 20.2 ± 9.4 49.6 ± 51.5a*** 20.9 ± 10.8 23.5 ± 11.4
Urea 20.5 ± 5.2 23.5 ± 8.7 20.8 ± 5.7 22.3 ± 4.1
Creatinine 0.85 ± 0.16 4.6 ± 11.7 0.8 ± 0.16 0.8 ± 0.24
Microalbuminuria (mg/dL) 16.4 ± 48.4 22.1 ± 33.9 15.1 ± 20.2 15 ± 16.4
For all the parameters mean ± SD is reported. aComparison between Control and T2DM, bComparison between T2DM and T2DM-CAD, cComparison between CAD
and T2DM-CAD. *P < 0.05, **P < 0.01, ***P < 0.0001.
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Figure 2 Serum levels of Th2 cytokines (IL-4, 5 and 13) in the study groups. Serum levels of IL-4 (a), IL-5 (b) and IL-13 (c) were determined
in control (NGT), T2DM, CAD and T2DM-CAD subjects by multiplex cytokines assay. Each dot represents individual values with the horizontal line
representing the geo mean. Statistical significance was determined by non-parametric Kruskal–Wallis one-way analysis of variance and p < 0.05
was considered significant.
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0.314; P < 0.0001), HbA1C (r = 0.439; P < 0.0001), VLDL
(r = 0.234, P = 0.004), AGI (r = 0.313, P = 0.047) and
negative correlation with CHO (r = −0.231; P = 0.003)
and LDL (r = −0.337; p = <0.0001). IL-5 showed a positive
correlation with FPG (r = 0.184; P = 0.02) and HbA1C
(r = 0.243; p = 0.004) whereas a negative correlation with
IMT(r = −0.376, p = 0.003) and AGI (r = −0.366, P = 0.018).
IL-13 showed a positive correlation with Age (r = 0.278,
P = 0.001), FPG (r = 0.244; P = 0.002), HbA1C (r = 0.312;
p < 0.0001), Triglycerides (r = 0.161; P = 0.041), VLDL
(r = 0.201; P = 0.014) and IMT (r = 0.341, p = 0.008).
Additional file 2: Table S2 shows the results of multivari-
ate logistic regression analysis. With NGT and T2DM as
dependent variables and the cytokines as independent
variables IL-13 (OR = 4.8, 95% CI 2.7-11.7, p = 0.048)
showed a strong and IL-12 showed a weak (OR = 1.9,
95% CI 1.5-2.7, p = 0.043) association with T2DM. With
NGT and CAD as dependent variable, IL-2 (OR = 1.8,
95% CI = 1.5-2.4, p = 0.010), IFN-γ (OR = 2.9, 95% CI =
2.7-3.2, p = 0.042) and IL-4 (OR = 2.7, 95% CI = 2.7-2.8,
p = 0.029) showed a significant association with CAD.
With CAD and T2DM-CAD as dependent variable onlyIL-4 (OR = 2.7, 95% CI = 2.6-2.7, p = 0.036) showed an
association with T2DM-CAD. However using T2DM
and T2DM-CAD as dependent variables, IL-12 (OR =
9.3;95% CI = 3.2-70.7;p = 0.016), IFN-γ (OR = 2.8; 95%
CI = 2.7-2.9, p = 0.010), IL-4 (OR = 2.7; 95% CI 2.7-2.7,
p = 0.010), IL-5 (OR = 1.1;95% CI = 1.0-1.4; p = 0.003)
and IL-13 (OR = 2;95% CI = 1.7-2.6; p = 0.017) showed
significant association with T2DM-CAD.
Discussion
Both T2DM and CAD are characterized by chronic, low
grade non-specific inflammation, which has long been
associated with sterile innate immune responses mediated
by heightened levels of serum pro-inflammatory cytokines
(TNF-a, IL-6 and IL-1b) [16]. However, recent identifica-
tion of T cells in the primary organs of inflammation
namely adipose (in the case of T2DM) and atherosclerotic
plaque (in the case of CAD) had induced renewed interest
in studying T cell cytokines in these disease conditions.
Recent studies have identified the potential of using im-
munomodulatory therapeutics to treat cardiovascular
events among T2DM subjects which included statins,
monoclonal antibodies and anti-inflammatory agents
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cytokines in subjects with T2DM, CAD and T2DM-CAD
co-morbidities. The major findings are as follows: 1.
T2DM subjects showed a mixed Th1-Th2 profile, 2. CAD
subjects presented a Th1 profile with reduced levels of
IL-5, 3. T2DM-CAD subjects showed Th1 profile with
strong suppression of all the Th2 cytokines 4. Both Th1
and Th2 showed a positive correlation with FPG,
HbA1c, hsCRP, IMT and AGI and 5. Logistic regression
analysis showed a significant association of IL-12, IFN-γ,
IL-4, IL-5 and IL-13 with T2DM-CAD even after adjusting
for age and gender.
In our previous study, we have reported a mixed Th1/
Th2 profile in subjects with Metabolic Syndrome (MS)
[7]. In the present study, we observed a similar “mixed
Th1/Th2 profile” in T2DM subjects. This similarity in
the serum cytokine profile between these related con-
ditions could be due to the common risk factors asso-
ciated with them (central obesity, dyslipidemia and IR).
In general, the association of Th1 cytokines with adi-
pose inflammation is well documented in both animals
and humans [18,19]. Obese IFN-γ deficient animals
had shown significant reduction in the expression of
mRNA-encoding inflammatory genes in adipose tissue
(AT) indicating the role of IFN- γ in adipose inflamma-
tion and IR [18]. Pacifico et al., has demonstrated an
increase in IFN-γ secreting CD4+ T cells in obese
children [19]. Furthermore, these CD4+ T cells showed
a positive association with leptin, insulin and HOMA-IR
[19]. Apart from IFN- γ, elevated levels of IL-12 have
been observed in patients with T2DM and were found
to be strongly associated with IR [20]. These reports
signify the role of Th1 cytokines in AT inflammation
and IR. However, the exact mechanism by which Th1
cytokines bring about IR is not clearly known. It could
be due to their interference with the insulin signalling
and insulin stimulated glucose uptake eventually lead-
ing to IR. Along with Th1 cytokines, a significant up-
regulation of Th2 cytokines (IL-4, IL-5, and IL-13) was
also seen in T2DM subjects. Data available on the Th2
serum cytokine profile in T2DM subjects is scant. In a
recent study, decreased serum levels of IL-13 in T2DM
subjects was reported which was implicated in im-
paired glucose uptake and metabolism [21]. Chang
et al., have demonstrated the role of IL-4 in improving
insulin sensitivity and glucose tolerance in an animal
model of diet induced obesity [22]. Thus with the
current finding and in the light of the available litera-
ture the increased levels of Th2 cytokines in T2DM
implicates a counter measure to inhibit Th1 immunity
and there by IR.
Next, we evaluated the T cell cytokine profile in CAD.
Apart from its role in IR, T-cells also play a critical role
in the initiation, progression and rupture of atheroscleroticplaque leading to CAD and other cardiovascular com-
plications. The presence of T-cells in atherosclerotic
plaques has been identified long back in the 1980s [4].
Hansson and co-workers have reported that most of the
atherosclerotic plaque cells express HLA-DR, indicating
continuous activation by IFN-γ [23]. The same group
has demonstrated the expression of IL-2 and IFN-γ in a
large proportion of the plaque [24]. In ApoE knock-out
mice, IFN-γ was shown to potentiate atherosclerosis
through both local and systemic effects [25]. IFN-γ has
also been proposed as a component of five panel marker
for the prediction of CAD in symptomatic patients re-
ferred for coronary angiography [26]. In contrast to Th1
cells, Th2 cells are rarely detected within the athero-
sclerotic lesions [27]. In line with these reports, we
found enhanced Th1 cytokine profile in CAD subjects
with significant decrease in IL-5 levels. Thus accumulat-
ing evidence suggests that an imbalance in the Th1/Th2
cytokines with enhanced Th1 immune response and
suppressed Th2 response, has an important role in the
pathogenesis of CAD [28].
Even though the pathophysiology of insulin resist-
ance and atherosclerosis may have a common inflam-
matory basis, the nature/type of inflammation per se
might be different between these conditions. In the
present study, T2DM-CAD subjects showed an en-
hanced Th1 polarization similar to that of CAD sub-
jects with further reduction in their Th2 cytokine
levels. In a previous study, it has been reported that Th1 to
Th2 ratio shifted more towards Th1 dominance in both
acute coronary syndrome and stable CAD [29]. The exact
cause for low levels of Th2 cytokines in T2DM-CAD is cur-
rently not known. Recently, autoantibodies have been im-
plicated in the lower levels of serum IL-5 as seen in CAD
[30]. It would be interesting to see whether autoantibodies
against IL-4 and IL-13 could account for the low levels of
these cytokines as seen in T2DM-CAD subjects. Till now
to the best of our knowledge even animal studies looking at
Th1-Th2 responses under the co-morbidity of T2DM and
CAD are not available to draw a corollary for our findings.Conclusion
In conclusion, from the present study and other avail-
able data, it appears that transition from T2DM/CAD to
T2DM-CAD co-morbidity is associated with strong
down regulation of Th2 cytokines and enhancement of
Th1 responses. The major limitation of our study is the
limited sample size of the CAD and T2DM-CAD group
and its cross-sectional nature, which means that no
cause and effect relationship can be drawn. Nevertheless,
this study gains importance in the context of it being
conducted in a high-risk ethnic population where no
reports on this topic are currently available.
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Additional file 1: Table S1. Spearman’s Correlation analysis of TH1/TH2
cytokines with the T2DM and CAD risk factors. Description of data: This
table contains the results (r, p value) of spearman’s correlation analysis of
TH1/TH2 cytokines with the T2DM and CAD risk factors.
Additional file 2: Table S2. Logistic Regression Analysis with disease
phenotype as dependent variable. Description of data: This table contains
the results (Odds Ratio (OR), p value, 95% confidence interval (C.I)) of
Logistic Regression Analysis performed with disease phenotype as
dependent variable.
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